Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak. The assays are designed for integration with the QIAcuity digital PCR system and for use by qualified laboratories in research, wastewater surveillance, and other environmental monitoring workflows. They were developed using publicly available genomic sequence information released during the outbreak response.

The new assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by the company. On the QIAcuity platform, dPCR enables sensitive nucleic acid detection and quantification across research applications, including infectious disease research and environmental surveillance, and the assays are part of a broader Sample to Insight portfolio that spans sample preparation through sequencing and analysis.

The assays are intended strictly for research use and are not intended for diagnostic procedures. They are available through a custom assay workflow on a make-to-order basis targeting the NP and VP35 regions. Complementary products available from stock include QIAseq sequencing panels and sample preparation and molecular workflow kits to support nucleic acid processing for downstream dPCR and next-generation sequencing (NGS).

The availability of these tools highlights the role of adaptable molecular technologies in supporting public health research infrastructure as genomic information emerges during outbreak responses. Combined with the QIAcuity system, the portfolio enables laboratories to rapidly adapt existing workflows as new pathogen targets arise. Further information on digital PCR solutions and custom assay workflows is available through local representatives or the customer care team.

“Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QIAGEN is committed to supporting customers around the world with adaptable molecular technologies that help strengthen infectious disease research and surveillance capacity. Our goal remains clear: no country should be left behind when new threats emerge.”